Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Infarction | 1 | 2020 | 206 | 0.70 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.42 | Why? |
| Hepatitis C | 5 | 2018 | 1514 | 0.34 | Why? |
| Hepatitis B, Chronic | 3 | 2018 | 616 | 0.31 | Why? |
| Antibodies, Monoclonal, Humanized | 9 | 2021 | 9335 | 0.28 | Why? |
| Mass Chest X-Ray | 1 | 2021 | 68 | 0.22 | Why? |
| Viscera | 1 | 2020 | 38 | 0.21 | Why? |
| Intra-Abdominal Fat | 1 | 2021 | 227 | 0.18 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.18 | Why? |
| Hepatitis D | 1 | 2018 | 48 | 0.18 | Why? |
| Social Security | 1 | 2018 | 24 | 0.18 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.17 | Why? |
| Body Composition | 1 | 2021 | 414 | 0.17 | Why? |
| Italy | 15 | 2021 | 38444 | 0.16 | Why? |
| Abdomen | 1 | 2020 | 424 | 0.16 | Why? |
| Antirheumatic Agents | 2 | 2021 | 3023 | 0.15 | Why? |
| Receptors, Interleukin-6 | 2 | 2021 | 1383 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Rheumatic Diseases | 2 | 2021 | 2675 | 0.14 | Why? |
| Models, Economic | 1 | 2017 | 316 | 0.14 | Why? |
| Coronaviridae | 1 | 2021 | 923 | 0.14 | Why? |
| Liver Cirrhosis | 4 | 2018 | 1810 | 0.14 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.13 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Antiviral Agents | 7 | 2020 | 41703 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.11 | Why? |
| Tomography, X-Ray Computed | 4 | 2021 | 25144 | 0.11 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.10 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.10 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| Geriatric Assessment | 1 | 2018 | 1372 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.08 | Why? |
| Noninvasive Ventilation | 1 | 2020 | 2329 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.08 | Why? |
| Substance-Related Disorders | 1 | 2021 | 2038 | 0.08 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.08 | Why? |
| Administration, Intravenous | 2 | 2020 | 1115 | 0.08 | Why? |
| Hepatitis B Surface Antigens | 2 | 2018 | 305 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.07 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Male | 22 | 2021 | 367725 | 0.07 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Aged | 15 | 2021 | 215776 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2017 | 5837 | 0.07 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Multicenter Studies as Topic | 2 | 2021 | 2437 | 0.06 | Why? |
| Purines | 2 | 2020 | 816 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Female | 21 | 2021 | 380317 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Drug Administration Schedule | 2 | 2020 | 2324 | 0.06 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.06 | Why? |
| Hepatitis B | 2 | 2017 | 888 | 0.06 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.05 | Why? |
| Registries | 1 | 2021 | 12327 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2020 | 121 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2021 | 7268 | 0.05 | Why? |
| Humans | 28 | 2021 | 930598 | 0.05 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.05 | Why? |
| Hepacivirus | 2 | 2017 | 1509 | 0.05 | Why? |
| Medical Futility | 1 | 2021 | 150 | 0.05 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.05 | Why? |
| Acute-Phase Proteins | 1 | 2020 | 177 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.05 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.05 | Why? |
| Abatacept | 1 | 2020 | 192 | 0.05 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Ustekinumab | 1 | 2020 | 216 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Superoxides | 1 | 2017 | 36 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2021 | 1256 | 0.04 | Why? |
| Calcium Channel Blockers | 1 | 2020 | 367 | 0.04 | Why? |
| Adult | 13 | 2021 | 244371 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2020 | 801 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Pyrroles | 1 | 2020 | 292 | 0.04 | Why? |
| Membrane Potential, Mitochondrial | 1 | 2017 | 102 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.04 | Why? |
| Markov Chains | 1 | 2018 | 502 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.04 | Why? |
| Hepatitis B virus | 1 | 2002 | 882 | 0.04 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.03 | Why? |
| Interferons | 2 | 2017 | 2885 | 0.03 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.03 | Why? |
| Piperidines | 1 | 2020 | 795 | 0.03 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.03 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.03 | Why? |
| Pyrimidines | 1 | 2020 | 1557 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.03 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.03 | Why? |
| Immunologic Memory | 1 | 2002 | 3362 | 0.03 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.02 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.02 | Why? |
| Acute Disease | 2 | 2017 | 6029 | 0.02 | Why? |
| Income | 1 | 2018 | 1564 | 0.02 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Canada | 1 | 2020 | 6018 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.02 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Population Surveillance | 1 | 2021 | 4967 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 45 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.02 | Why? |
| Perforin | 1 | 2002 | 136 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Membrane Glycoproteins | 1 | 2002 | 2273 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
Massari's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(154)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(297)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_